-
Fighter. Hero. Cancer-stricken. The words and metaphors people use to talk about cancer often feel worlds apart from any other disease. But how far does it go? Do words matter?
CancerDisease AwarenessLiving With DiseaseOncology -
Ad hoc announcement pursuant to Art. 53 LRReimagine MedicineOncologyMedical InnovationsCancerAd Hoc
-
Basel, December 6, 2022 — Novartis today announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-…Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, December 13, 2022 — Novartis today announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy. Pluvicto® is approved in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition, for the treatment of adult…Reimagine MedicineOncologyMedical InnovationsCancer
-
Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, June 30, 2022 — In early June, Novartis restarted radioligand therapy (RLT) production at its sites in Ivrea, Italy, and Millburn, New Jersey, and resumed delivery of doses to patients in a phased approach, ahead of the expected six-week timeframe. The company has remediated the issues that led to the temporary, voluntary suspension of…Reimagine MedicineOncologyCancer
-
Basel, June 30, 2022 — Today Novartis announced results from the Phase III RATIONALE 306 trial showing tislelizumab plus chemotherapy significantly improved overall survival (OS) as a first-line treatment for adult patients with unresectable, locally advanced or metastatic esophageal squamous cell carcinoma (ESCC), regardless of PD-L1 status.…Reimagine MedicineOncologyCancer
-
Basel, August 15, 2022 — Novartis announced today that the Phase III CANOPY-A study evaluating adjuvant treatment with canakinumab (ACZ885), an inhibitor of interleukin-1beta (IL-1β), in adult patients with stages II-IIIA and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC) did not meet its primary endpoint of…OncologyCancer
-
Basel, August 30, 2022 — Novartis will showcase new data from across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2022 with over 35 accepted abstracts from Novartis-sponsored and investigator-initiated trials including new data in advanced breast cancer and metastatic castration-resistant prostate cancer.Reimagine MedicineOncologyMedical InnovationsCancer
-
Basel, September 9, 2022 — Novartis today announced results from a new pooled exploratory analysis across the entire MONALEESA Phase III program, confirming nearly one year of additional overall survival (OS) benefit in a subgroup of patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR…Reimagine MedicineOncologyCancer
-
Basel, September 10, 2022 — Novartis today announced new data from the Phase III RATIONALE 301 trial that show tislelizumab demonstrated non-inferior overall survival (OS) compared to sorafenib (median OS: 15.9 months vs. 14.1 months; stratified HR=0.85 [95.003% CI: 0.712, 1.019]) in patients with previously untreated, unresectable hepatocellular…Reimagine MedicineOncologyCancer
-
Basel, October 14, 2022 — Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting a marketing authorization for Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617), a…Reimagine MedicineOncologyMedical InnovationsCancer